PT - JOURNAL ARTICLE AU - Janev Fehmi AU - Roberto Bellanti AU - Siraj A Misbah AU - Anupam Bhattacharjee AU - Simon Rinaldi TI - Treatment of CIDP AID - 10.1136/pn-2021-002991 DP - 2022 Sep 15 TA - Practical Neurology PG - pn-2021-002991 4099 - http://pn.bmj.com/content/early/2022/09/14/pn-2021-002991.short 4100 - http://pn.bmj.com/content/early/2022/09/14/pn-2021-002991.full AB - Chronic inflammatory demyelinating polyneuropathy is a disabling but treatable disorder. However, misdiagnosis is common, and it can be difficult to optimise its treatment. Various agents are used both for first and second line. First-line options are intravenous immunoglobulin, corticosteroids and plasma exchange. Second-line therapies may be introduced as steroid-sparing agents or as more potent escalation therapy. It is also important to consider symptomatic treatment of neuropathic pain and non-pharmacological interventions. We discuss the evidence for the various treatments and explain the practicalities of the different approaches. We also outline strategies for monitoring response and assessing the ongoing need for therapy.All data relevant to the study are included in the article.